|
|
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVITY DESCRIPTION
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ... |
|
|
Cleveland Clinic 27th Annual Diabetes Therapeutics, Technology and Surgery (Online Streaming On Demand)
For over a quarter century, Cleveland Clinic has been at the forefront of continuing education regarding the treatment and management of diabetes. Its world class faculty has designed the 27th Annual Diabetes Therapeutics, Technology and Surgery to provide up-to-date reviews of strategies and research relevant to this disease and its complications. The goal of this activity is to increase practitioners’ competence and clinical performance in the management of type 1 and type 2 diabetes. A... |
|